<unk>  is an antineoplastic agent that is FDA approved for the treatment of cutaneous lesions in patients with CTCL (Stage IA and IB) who have refractory or persistent disease after other therapies or who have not tolerated other therapies..   Common adverse reactions include rash, pruritus, skin disorder, and pain, peripheral edema, dry skin, photosensitivity, hypothyroidism, abdominal pain, nausea, asthenia, and headache.
Bexarotene
Tazarotene
Retinol
Metenolone enanthate
Calcipotriol
Desonide
Fluocinonide
Carotene